ArticlePain research & management
Use of lidocaine patches for neuropathic pain in a comprehensive cancer centre.
Article in Pain research & management. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Survivorship: pain version 1.2014.Journal of the National Comprehensive Cancer Network : JNCCN · 2014Guideline
- Adult cancer pain.Journal of the National Comprehensive Cancer Network : JNCCN · 2013Guideline
- Incobotulinum Toxin-A Improves Post-Surgical and Post-Radiation Pain in Cancer Patients.Toxins · 2016Trial
- Lidocaine 5 % patches as an effective short-term co-analgesic in cancer pain. Preliminary results.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013Trial
- A comprehensive review on pain: Model, target, therapy, and prospect (Review).International journal of molecular medicine · 2026Review
- Lidocaine transdermal patches reduced pain intensity in neuropathic cancer patients already receiving opioid treatment.BMC palliative care · 2023Article
- Review
- Article
- LP1 and LP2: Dual-Target MOPr/DOPr Ligands as Drug Candidates for Persistent Pain Relief.Molecules (Basel, Switzerland) · 2021Review
- Review
- Chronic postsurgical pain: current evidence for prevention and management.The Korean journal of pain · 2018Review
- Novel Treatment of Radicular Pain With a Multi-Mechanistic Combination Topical Agent: A Case Series and Literature Review.Anesthesiology and pain medicine · 2016Article
- Treatment of acute and chronic focal neuropathic pain in cancer patients with lidocaine 5 % patches. A radiation and oncology department experience.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013Article
- Can treatment success with 5% lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain?Journal of pain research · 2013Article
- Topical preparations for pain relief: efficacy and patient adherence.Journal of pain research · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are few reports of the use of the lidocaine 5% patch (L5%P) for neuropathic pain (NP) in the cancer patient. Within a comprehensive cancer centre, L5%P has been prescribed by the Pain and Palliative Care Service (Peter McCallum Cancer Centre, East Melbourne, Victoria, Australia) for selected patients with NP since 2001.
objectiveTo retrospectively audit the use of L5%P within a comprehensive cancer centre.
methodsAll L5%P prescriptions up to January 2009 were listed and patient medical records were searched to determine neuropathic pain syndromes treated, the presence of allodynia, previous analgesic medications, treatment duration and outcome.
resultsL5%P was prescribed for 97 patients, most frequently for persistent postsurgical NP (n=26), postherpetic neuralgia (n=24) and cancer-related NP (n=18). Six patients had no history of cancer and two patients never applied L5%P. Reviewers classed L5%P analgesic efficacy as 'potent' in 38% of patients with postherpetic neuralgia, 35% of patients with postsurgical pain, 27% of patients with NP after other treatments for cancer and 12% of patients with NP attributed to cancer alone. Allodynia featured in at least 60% of patients. Where allodynia was present, the efficacy of L5%P was assessed as 'potent' in 38% and 'partial' in 24%, but 'ineffective' in 26%, and 'causing worse pain' in 3.4% of patients. Treatment duration extended longer than one month in 52 patients, longer than two months in 29 patients and longer than one year in 13 patients. Therapy was ceased due to skin irritation in seven patients. The outcomes in relation to other reports are discussed.
conclusionThe present data support trials of L5%P for cancer patients with NP syndromes associated with allodynia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.